The UK’s life sciences sector, a vital organ of the national economy, is in critical condition. A diagnosis reveals a severe hemorrhage of investment, a breakdown in the relationship between industry and government, and a poor prognosis if immediate intervention is not undertaken. The sense of urgency is palpable, as the window to save this prized asset is rapidly closing.
Symptoms of the decline are acute and highly visible. Pharmaceutical giant MSD pulled the plug on a £1 billion research centre, a clear vote of no confidence. This was followed by similar moves from Eli Lilly, which suspended its lab plans, and Sanofi, which is actively winding down its UK clinical trials. These are not minor ailments but signs of systemic failure.
The underlying causes are chronic and deeply embedded in UK policy. The industry has been weakened by years of low government spending on medicines, a pricing system that fails to reward innovation, and punishingly high revenue clawbacks. An internal government dispute over spending has prevented any meaningful treatment from being administered, leaving the sector to languish.
The UK’s residual strengths—its world-class universities and skilled scientists—are like a strong constitution, but they cannot fight the disease alone. The commercial environment is becoming toxic for growth and innovation. The government must now perform radical surgery on its policies, or it will have to sign the death certificate for the UK’s status as a life sciences leader.
On Life Support: The Critical Condition of UK’s Science Sector
